Urinary Tract Infection Treatment Market Insights, Growth Drivers, Industry Segmentation by 2024

Urinary Tract Infection Treatment Market size is projected to experience significant growth from 2017 to 2024.

Urinary tract infection (UTI) treatment market size should witness significant growth due to increasing prevalence of urinary tract infections. The females are much more susceptible to this disease compared to the males. Increased sexual activity, use of certain birth control measures such as diaphragm and menopause further increases the risk. Increasing antimicrobial resistance and high recurrence rates pertaining will serve to be high impact rendering factor.

Request for a Table of Contents of this research report – https://www.gminsights.com/request-toc/upcoming/2008

Diabetes and obesity are among the major risk factor and prevalence of these disease is rising across the globe. Increased blood glucose level and defective immune system in diabetes mellitus considerably increases the chances of infection. Pregnancy, long term use of catheters, immune suppression and urologic abnormalities are some other risk factor than may increase the incidences of the urinary tract disease. Growing obesity rates should further drive the urinary tract infection treatment market across over forecast timeframe.

Emerging technologies for the accurate and timely diagnosis should increase the number of diagnosed cases and will help to treat patients more effectively. Emerging technologies such as microfluidics and biosensors will improve diagnosis of disease enhancing patient care. Such technological advancements will boost the urinary tract infection treatment market over the forecast period. Excessive cost associated with the R&D coupled with increasing awareness leading to the prevention of infection should limit the urinary tract infection treatment market growth to some extent.

Fluoroquinolones drug segment is expected to show robust growth over forecast period as it is most commonly prescribed by the physicians. Ciprofloxacin, levofloxacin, and enoxacin are among the most widely used drugs for treatment. Optimal pharmacokinetics, availability in oral dosage form and effectiveness against multidrug-resistant organism is expected to boost the fluoroquinolone dug segment growth. Complicated urinary tract infection occurs in individual with functional and structural abnormalities in the genitourinary tract is highly prevalent in renal failure. The increasing microbial resistance rendering this type is difficult to treat. Failure of current medicines to treat resistant microbes will fuel the demand for better treatment options.

Online pharmacy segment will grow over the forecast period due to increasing number of online pharmacies. The lower cost of drugs and convenience associated with the online pharmacies should further propel the segment growth. However, the substantial number of illegitimate online pharmacies selling fake products and stringent regulation governing the online pharmacies will restrict the segment growth to some extent.

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/2008

U.S will witness significant growth over the forecast period due to presence of large patient pool. According to Centers for Disease Control and Prevention around 8 million people suffered from urinary tract infection every year and around 80% of women in U.S. are diagnosed with infection at least once in lifetime. Asia pacific is expected to show rapid growth over forecast period owing to the rapidly aging population, high prevalence of chronic diseases like diabetes and renal failure. The lack of awareness in the region will restrain the urinary tract infection treatment market growth to some extent.

Some of the industry players are Roche, Pfizer, Cipla, Johnson & Johnson, Bayer, GlaxoSmithKline, Emcure pharmaceuticals, Biosense Webster, St. Jude Medical, Cardiofocus, Articure, Biotronik, and Cardima. Actavis, Zerbaxa, Forest Laboratories and Depomed. The industry players focus innovative product launch to expand their business portfolio as main strategies. For instance, Roche diagnostics launched automated testing analyzer for the accurate diagnosis of the urinary tract infections. Companies operating in this market have been also trying to gain approvals for various dosage forms to fasten the treatment duration. Like, Zydus Pharma on June 1, 2017 got approval for Levofloxacin injectable.